Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued
Reference number: GID-TA10418
The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of pembrolizumab with chemotherapy for treating advanced or metastatic urothelial cancer. We invited stakeholders to respond to a written consultation on the draft scope for this appraisal which closed on 16 May 2019.
On receiving updated regulatory timing information from the company that is developing pembrolizumab, NICE has agreed that holding a scoping exercise at this time would not be appropriate. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause.
If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk)